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Deletion and duplication of 16p11.2 are
associated with opposing effects on visual
evoked potential amplitude
Jocelyn J. LeBlanc1,2,3 and Charles A. Nelson1,4*
Abstract
Background: Duplication and deletion of the chromosomal region 16p11.2 cause a broad range of impairments,
including intellectual disability, language disorders, and sensory symptoms. However, it is unclear how changes in
16p11.2 dosage affect cortical circuitry during development. The aim of this study was to investigate whether the
visual evoked potential (VEP) could be used as a noninvasive quantitative measure of cortical processing in children
with 16p11.2 copy number variation.
Methods: Pattern-reversal VEPs were successfully recorded in 19 deletion carriers, 9 duplication carriers, and 13
typically developing children between the ages of 3 and 14 years. The stimulus was a black and white
checkerboard (60’) that reversed contrast at 2 Hz. VEP responses were extracted from continuous EEG recorded
using a high-density elasticized electrode net.
Results: Quantitative analysis of the VEP waveform revealed that, relative to controls, deletion carriers displayed
increased amplitude and duplication carriers displayed diminished amplitude. Latencies of the VEP waveform
components were unaffected by 16p11.2 status. P1 amplitude did not correlate with age, IQ, or head
circumference.
Conclusions: The results of this study suggest that recording VEP is a useful method to assay cortical processing in
children with 16p11.2 copy number variation. There is a gene dosage-dependent effect on P1 amplitude that
merits further investigation. The VEP is directly translatable to animal models, offering a promising way to probe the
neurobiological mechanisms underlying cortical dysfunction in this developmental disorder.
Keywords: 16p11.2 copy number variation, Visual evoked potential, Visual cortex
Background
Copy number variation of the 16p11.2 chromosomal re-
gion (16p CNV) is associated with developmental delay
and a wide range of physical abnormalities, behavioral
problems, and intellectual deficits [1]. Some features are
similarly manifested in deletion and duplication carriers,
such as seizures and cognitive impairment [1], and
others are affected in opposite ways, including head cir-
cumference and body weight [2, 3]. This begs the ques-
tion of whether brain function is affected in a gene
dosage-dependent manner. Although progress is being
made on characterizing the disorder and parsing the
neurobiological mechanisms, there remains a gap in our
understanding of how these genetic changes ultimately
produce the varied cognitive and behavioral outcomes in
this population.
Abnormal processing of sensory information is emer-
ging as a common problem in neurodevelopmental disor-
ders [4, 5], and testing sensory modalities like vision offers
an easily accessible window into cortical processing. Ab-
normalities of basic sensory processing may contribute to
and be indicative of global cortical deficits that would be
expressed as intellectual and behavioral deficits. A recent
study reported delayed auditory evoked responses using
magnetoencephalography in deletion but not duplication
carriers [5]. We were interested in whether this deficit
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would also pertain to the processing of visual information.
Vision is an ideal system because it is evolutionarily con-
served between rodents and humans, well characterized,
easily tested in a standardized manner, and relevant to
socialization, communication, and cognition.
Recording pattern-reversal visual evoked potentials
(VEPs) is a powerful method to noninvasively assess the
integrity of cortical processing in babies and children,
even those with profound disabilities [4, 6]. Eliciting
VEP involves a quick and passive procedure that only re-
quires fixation on a monitor, and the evoked response is
stable and robust enough to produce a recognizable
waveform after only a few trials. The waveform shape
elicited by this particular large check stimulus matures
within the first 2 years of life [7–11], and group differ-
ences in latency and amplitude can be quantified [4, 12].
Here, we recorded pattern-reversal VEP in children carry-
ing 16p deletions and duplications. Our goals were to assess
if the VEP could detect differences in cortical processing be-
tween typically developing children and those with 16p
CNV and between those with deletions and duplications.
We predicted that the latency and/or amplitude of visual
responses would either be similarly affected by 16p deletion
and duplication due to a common effect of disruption of this
chromosomal region on synapses and circuitry, or would be
differentially affected by 16p copy number due to a gene
dosage effect on the wiring of the visual cortex [5, 13, 14].
Methods
Participants
All procedures were reviewed and approved by the
Boston Children’s Hospital (BCH) Office of Clinical In-
vestigation and the BCH Institutional Review Board, and
written informed consent was obtained from each par-
ticipant or guardian prior to testing. Individuals carrying
16p11.2 deletions and duplications were recruited to
participate in the study through the Simons Variation in
Individuals Project (SVIP). Eligibility and exclusionary
criteria are described previously [5]. Typically developing
children were recruited through the BCH participant
registry and did not have any neurological or developmen-
tal disorders, seizures, and ophthalmological problems.
Data were collected onsite at BCH and at SVIP family
meetings in Orlando, Florida, and Chicago, Illinois.
The final dataset included 19 deletion carriers and 12
duplication carriers and a comparison group of 15 typic-
ally developing controls between 3 and 14 years old. Sev-
eral participants in the study were tested but were
excluded from further VEP analysis because noncompli-
ance prevented completion of data collection (2 duplica-
tion carriers), technical issues occurred at the time of
acquisition (2 controls), or an insufficient number of tri-
als remained after artifact detection (1 duplication car-
rier). Participant information is summarized in Table 1.
Phenotypic information was obtained from the Simons
Foundation Autism Research Initiative (SFARI) Base
(www.sfari.org/resources/sfari-base). Full-scale intelligence
quotient (IQ) scores were derived without adjusting for pre-
maturity and were only used if taken within 6 months of
the VEP session date. IQ was not assessed for typically de-
veloping participants because they were recruited inde-
pendently through BCH and did not undergo the SFARI
phenotypic battery. However, because the typically develop-
ing sample was drawn from a database of nearly 20,000
families and we have previously assessed IQ in a subset of
these children as part of another project, we expect the IQ
of our current group is average to above average. Autism
spectrum disorder status was determined based on the
diagnosis given by experienced, licensed clinicians. Seizure
history was available for 11/19 deletion carriers and 6/9 du-
plication carriers through the SFARI neurologic record re-
view form. Of these individuals, 4 deletion carriers and no
duplication carriers had a history of seizures. Current medi-
cation information was available for 7/19 deletion carriers
and 4/9 duplication carriers through the SFARI medication
questionnaire. Of these individuals, 2 deletion carriers and
no duplication carriers were currently taking antiepileptic
drugs at the time of the VEP session.
Participants were not given an ophthalmological exam
at the time of the VEP session due to budget and time
constraints, but information related to eye surgeries,
cataract, coloboma, glaucoma, and corrected vision was
available on the SFARI developmental and medical his-
tory form for 17/19 deletion carriers and 8/9 duplication
carriers. A total of 7 deletion carriers and 3 duplication
carriers were reported to have corrected vision but no
other uncorrected visual problems.
Visual evoked potential recordings
Pattern VEPs were recorded as described previously [4].
Participants sat 60 cm from a Tobii Eye Tracker monitor
(Tobii Technology, Sweden). Phase reversing 99 % con-
trast black and white checkerboard patterns were pre-
sented on the monitor using ePrime software (Psychology
Software Tools Inc., Pittsburgh, PA, USA). The diagonal
check size was 0.5 cycles/degree (60’), and the reversal rate
was once every 500 ms. Approximately 50–100 trials were
presented to each participant, and VEP sessions lasted no
longer than several minutes. Stimulus presentation was
experimenter-driven based on verification of binocular fix-
ation on the monitor.
Continuous electroencephalogram (EEG) was recorded
from a 128-channel HydroCel Geodesic Sensor Net (Elec-
trical Geodesics Inc., Eugene, OR, USA), referenced to Cz,
amplified with a NetAmps 300 amplifier, and digitized at
500 Hz. Data were analyzed offline using NetStation 4.5.4
software. The signal was filtered (0.3–30 Hz), segmented
into 300 ms post-stimulus recording periods, and baseline-
LeBlanc and Nelson Molecular Autism  (2016) 7:30 Page 2 of 7
corrected against the mean voltage during the 100 ms pre-
stimulus period. A 34-ms offset that was consistent for all
participants was accounted for at this point in the analysis
(16 ms between the stimulus trigger and appearance on the
monitor and 18 ms due to anti-aliasing filters within the
Electrical Geodesics Inc. NetAmps 300 amplifier).
An automated artifact detection tool flagged channels
with excessive voltage change (>150 uV), and bad chan-
nels were replaced using spherical spline interpolation.
Trials were removed if more than 10 % of channels were
flagged or if the electrode of interest Oz was marked bad
by artifact detection. Trials containing eye blinks, eye
movements, or excessive noise or drift based on visual in-
spection were also removed from subsequent analysis.
Average waveforms for each participant were generated
and re-referenced to the average reference. Participants
with fewer than 25 remaining trials were excluded from
the dataset. There was no significant difference in the
number of good trials between groups (Table 2).
Visual evoked potential analysis
We analyzed activity over the midline occipital electrode
Oz. The N1, P1, and N2 components were identified for
each participant’s average waveform, which are equivalent
to the N75, P100, and N135 [12] or the C1, P1, and N1
[15], respectively. The P1 was identified visually as the first
prominent positive inflection point closest to 100 ms and
occurred within 56–132 ms post-stimulus onset for all
participants. The N1 was the negative inflection point im-
mediately preceding the P1 and occurred within 0–70 ms
post-stimulus onset for all participants. The N2 was the
first negative inflection point following the P1 (or the last
peak in a series of multiple peaks, as described previously
[4]) and occurred within 108–266 ms post-stimulus onset
in all participants. The absolute amplitude and latency of
each component, as well as the relative amplitudes and
times between components, were quantified for each indi-
vidual’s average waveform.
Statistical analysis
Statistical analysis was performed with IBM SPSS Statis-
tics v.21 software. All data were analyzed blind to group
and based on biological replicates (each data point is
from one participant). Nonparametric tests were used
due to small sample sizes and non-normal distribution
of data. Results were considered significant if p < 0.05.
The three participant groups (control, deletion, and du-
plication) were compared using a Kruskal-Wallis test, re-
ported as H(df ) where H is the test statistic and df is the
degrees of freedom. If significant, the Kruskal-Wallis test
was followed by paired comparisons with adjusted p values.
Spearman correlations were used to compare the relation-
ships between continuous variables.
Results
We obtained usable data from 19 out of the 19 deletion
carriers, 9 out of the 12 duplication carriers, and 13 out
of the 15 control children tested (aged 3–14 years)
(Table 1). Individual and group average waveforms are
displayed in Fig. 1. Control waveforms were consistent
with those reported in the literature, containing clearly
identifiable N1, P1, and N2 components [12]. Deletion
carriers had VEP waveforms that were generally larger
and had a sharp return after peak response, while dupli-
cation carriers had VEPs that were smaller in amplitude
and more heterogeneous in morphology (Fig. 1).
When comparing the three groups, no differences in
latencies of any component were apparent, with the ex-
ception of a difference in N1 latency that did not remain
significant for any paired comparisons (Table 2). Instead,
there was a consistent effect on the amplitude of the
principal positive component (P1), including absolute P1
amplitude and relative N1-P1 and P1-N2 amplitudes.
This effect was due to a tendency towards large ampli-
tudes in deletion carriers and small amplitudes in dupli-
cation carriers (Table 2, Fig. 1).
Consistent with the literature on the maturation of the
pattern-reversal VEP [7–11], we observed no association
between age and quantification of the VEP in any of our
groups (Table 3). A relationship between IQ and pattern-
reversal VEP amplitude has been reported in older chil-
dren and adults [16]. As part of the Simons VIP project,
IQ was assessed for most 16p individuals (17/19 deletion
carriers and 7/9 duplication carriers). The deletion and
Table 1 Description of study participants
Group N Age (months)
median, range
Gender CNV inheritance ASD
De novo Inherited ? Yes No ?
Control 13 60 (39–165) 5 M – – – – – –
8 F – – – – – –
Deletion 19 62 (43–163) 10 M 6 1 3 2 6 2
9 F 7 1 1 3 6 0
Duplication 9 70 (40–122) 5 M 0 4 1 1 4 0
4 F 1 2 1 0 3 1
M male, F female, CNV copy number variant, ASD autism spectrum disorder
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duplication groups were well-matched for IQ (deletion:
median = 81, mean = 82, range = 60–116; duplication: me-
dian = 81, mean = 83, range = 72–114). IQ was not
assessed in our control group due to the design of
the study, and we did not have enough duplication
carriers with IQ measurements to perform a mean-
ingful correlation. We failed to observe any correl-
ation between IQ and any element of the VEP in our
16p deletion sample (Table 3).
Head size is known to be differentially affected by
16p11.2 copy number variation [1] and this could impact
VEP latency and/or amplitude [17, 18]. Head circumfer-
ence was measured at the beginning of the session in
order to select an appropriate size net for each participant.
While there was no statistically significant difference in
head size between groups (H(2):4.06, p = 0.131), children
carrying 16p duplications did tend to have smaller heads
(TD: median = 52.0, mean = 52.4, range = 48.5–55.5; dele-
tion: median = 51.5, mean = 52.4, range = 48.0–58.0; dupli-
cation: median = 49.8, mean = 50.1, range = 46.0-53.0;
unit = cm). There was also no correlation within any
group between head circumference and any VEP measure-
ment, including N1-P1 amplitude (TD: r = 0.47, p = 0.127;
deletion: r = 0.17, p = 0.494; duplication: r = 0.26; p = 0.108).
Taken together, differences in head size are unlikely to ex-
plain the group differences in N1-P1 amplitude.
16p11.2 CNV syndrome increases the risk for autism
spectrum disorder (ASD), particularly for those carrying
deletions [19, 20]. Only a small number of individuals in
our dataset had a confirmed diagnosis of ASD (n = 5 de-
letion carriers, n = 1 duplication carrier), and we desig-
nated these individuals as open circles in the scatter
plots in Fig. 1c, d in order to visualize any trends. All in-
dividuals with ASD had P1 latencies close to the median
value for their respective group (Fig. 1c). Individuals
with ASD tended to have P1 amplitudes above the me-
dian value for their respective group. This result indi-
cates that individuals carrying 16p deletions and a
diagnosis of ASD may have larger VEP amplitudes, but
future analysis of larger datasets is necessary.
Discussion
The differing effect of 16p11.2 deletion and duplication
on VEP P1 amplitude is intriguing and may offer insight
into the neural differences between the two genetic con-
ditions. It is known that deletion and duplication have
opposite effects on head circumference (macrocephaly
and microcephaly, respectively) [1], brain volume [13],
and white matter microstructure [21]. Little is under-
stood about how brain size and volume may affect VEP
amplitude measured from the scalp, but this could be a
contributing factor. It must also be considered that
Table 2 Quantification of VEP components and comparison between groups
Control Deletion Duplication Group comparisons Pairwise comparisons
Good trials 63 (49) 60 (39) 45 (47) H(2): 0.22, p = 0.894 –
Latency measurements (ms)
N1 latency 60 (15) 46 (30) 46 (16) H(2): 6.85, p = 0.033 Ctr/Del: p = 0.053
Ctr/Dup: p = 0.099
Del/Dup: p = 1.000
P1 latency 94 (9) 92 (12) 90 (7) H(2): 1.72, p = 0.422 –
N2 latency 164 (71) 164 (44) 152 (81) H(2): 0.13, p = 0.937 –
P1-N2 time 72.0 (66.0) 72.0 (50.0) 72.0 (76.0) H(2): 0.37, p = 0.858 –
Amplitude measurements (uV)
N1 amp −4.5 (5.1) −1.2 (5.4) −3.4 (4.3) H(2): 3.97, p = 0.137 –
P1 amp 10.4 (8.1) 15.7 (11.2) 5.4 (9.5) H(2): 11.92, p = 0.003 Ctr/Del: p = 0.088
Ctr/Dup: p = 0.628
Del/Dup: p = 0.003
N2 amp −0.94 (11.5) −7.45 (7.3) −3.19 (7.2) H(2): 1.55, p = 0.460 –
N1-P1 amp 15.0 (17.5) 16.9 (6.1) 8.3 (11.1) H(2): 6.81, p = 0.033 Ctr/Del: p = 1.000
Ctr/Dup: p = 0.226
Del/Dup: p = 0.028
P1-N2 amp 12.9 (17.6) 19.7 (16.4) 8.1 (10.3) H(2): 10.48, p = 0.005 Ctr/Del: p = 0.207
Ctr/Dup: p = 0.455
Del/Dup: p = 0.005
Median values (interquartile range) are reported. Amp: amplitude. Pairwise comparisons with adjusted p values were performed if the overall group comparison
was significant (p < 0.05). Significant results are in bold
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reduced cortical thickness has been reported in both de-
letion and duplication carriers [22], a finding that may
be particularly relevant for a cortical recording method
like VEP.
A reduction in P1 amplitude of the VEP has been
found in psychoses [23–25], and 16p11.2 CNVs are asso-
ciated with schizophrenia and bipolar disorder [20, 26].
This potential association could be investigated further
in an older cohort of individuals with 16p11.2 CNVs.
A similar increase in VEP P1 amplitude has been
found in mice carrying deletion of 16p11.2 (S. Cooke
and M. Bear, personal communication). If this holds
true, this parallel result could validate the translatable
relevance of the mouse model to the human condition
and will ultimately help us to better understand the syn-
aptic and circuit mechanisms underlying cortical dys-
function in 16p CNV syndrome. Some recent in-depth
analysis of cortical organization has been done in mice
Table 3 Correlations with age and IQ
Correlation with age Correlation with IQ
Measurement Control Deletion Duplication Deletion
r P r P r P r P
N1 latency −0.02 0.957 −0.11 0.665 −0.66 0.052 −0.15 0.567
P1 latency 0.13 0.667 0.17 0.483 0.00 0.991 −0.35 0.163
N2 latency 0.37 0.220 0.02 0.950 0.03 0.932 0.07 0.793
P1-N2 time 0.41 0.162 −0.07 0.782 0.17 0.672 0.18 0.500
N1 amp −0.10 0.747 −0.10 0.673 0.02 0.966 −0.19 0.455
P1 amp −0.07 0.830 −0.18 0.468 −0.03 0.932 −0.09 0.729
N2 amp 0.08 0.788 0.22 0.359 −0.41 0.271 0.20 0.444
N1-P1 amp 0.09 0.774 0.15 0.552 −0.13 0.730 0.05 0.844
P1-N2 amp −0.11 0.719 −0.14 0.569 0.09 0.813 −0.06 0.829
Amplitude (amp) values are in uV and latency (lat) or time values are in milliseconds. Spearman correlations were performed and the correlation coefficient (r) is
reported. Correlation with IQ was only performed within the deletion group
a
b c d
Fig. 1 VEP waveforms in children with 16p11.2 deletions and duplications. a Averaged waveforms are displayed for each individual (thin traces) and each
group (thick traces) for controls (black), deletion carriers (blue), and duplication carriers (green). The x-axis plots time in milliseconds, where −100 to 0 is the
baseline period, 0 is the onset of the stimulus, and 0 to 300 is the response to the stimulus. The y-axis plots amplitude in microvolts. b Group average
responses are displayed in an overlapping fashion to facilitate comparison between groups. c P1 latency is quantified for each individual. Open circles
indicate individuals with a positive diagnosis for ASD. The line indicates the median for each group. d P1 amplitude is quantified for each individual. Open
circles indicate individuals with a positive diagnosis for ASD. The line indicates the median for each group. **p < 0.01
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carrying 16p deletions. Specifically, these mice display
fewer upper layer pyramidal cells and increased layer 6
corticothalamic projection neurons due to ERK dysregu-
lation [14]. Such changes in cortical microcircuitry could
contribute to the changes in VEP amplitude observed in
both mice and humans.
Interestingly, auditory responses measured using mag-
noencephalography were reported to be delayed in chil-
dren with 16p deletions but not duplications, and there
was no contribution of age or IQ to this result [5]. The
representative traces displayed in the first figure of that
paper appear to show increased signal amplitude in dele-
tions and decreased amplitude in duplications; however,
quantification of amplitude was not reported so this may
not be a significant finding. Here, we used EEG to assess
visual processing in our study and found differences in
amplitude and not latency. It is unclear if our findings
differ due to the sensory system that was being assessed
or the method used.
Limitations of our study
One potential limitation of our study is the broad age
range of our sample that spans childhood. However, the
VEP is mature by 2 years of age [7–11], which is well
below the age of our youngest participant, and we saw
no effect of age on any VEP component within any
group. Another limitation is the small sample size and
variability of phenotype and comorbid conditions, includ-
ing seizure history, medication use, and ASD diagnosis.
This is a challenge inherent in studying this population
and means that any differences that emerge from group
comparison are then potentially specific to the genetic con-
dition. Cognitive ability is one phenotypic variable that we
were not able to adequately address in this study because
IQ was not assessed in the typically developing group due
to the nature of the study design. IQ did not differ between
the 16p deletion and duplication groups, however, and be-
cause there was no correlation between IQ and VEP ampli-
tude in the deletion group, IQ is not likely to explain the
differences in P1 amplitude in our dataset.
Finally, because visual information must first travel
through the retina and thalamus before reaching the
cortex where the VEP is recorded, we cannot exclude
that ophthalmological abnormalities could contribute to
any group differences we see. However, no participant
was reported to have had eye surgery, cataract, colo-
boma, glaucoma, or any other uncorrected visual prob-
lems. In addition, the latency of the components was
unaffected, suggesting that the arrival of visual informa-
tion from the periphery to the cortex was intact.
Conclusions
Our study has shown that it is possible to successfully
record VEP in children with 16p11.2 CNV disorder who
present with a range of intellectual, behavioral, and
physical disabilities. We have shown that VEP responses
are robust, easily quantifiable, and unaffected by age,
head circumference, or IQ. Furthermore, the amplitude
of the principal P1 component is enhanced in deletion
carriers and diminished in duplication carriers, providing
a biomarker to further probe cortical processing in the
two conditions.
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